Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arya Sciences Acquisition Corp IV Cl A (NQ: ARYD ) 6.640 UNCHANGED Last Price Updated: 3:59 PM EDT, Jul 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Arya Sciences Acquisition Corp IV Cl A Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias July 31, 2024 From Adagio Medical, Inc. Via Business Wire Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider May 06, 2024 From GENENTA SCIENCE SPA Via GlobeNewswire Stocks That Hit 52-Week Lows On Friday February 25, 2022 During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week... Via Benzinga Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall February 24, 2022 Amicus Therapeutics Inc (NASDAQ: FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.' With "market... Via Benzinga The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company February 24, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... Via Benzinga The Week In SPAC News - Sunday, Oct. 3 October 03, 2021 In SPAC news this week, Amicus Therapeutics announced its intent to sell its gene therapy unit to ARYA Sciences Acquisition Corp IV, a SPAC sponsored by Perceptive Advisors. Via Talk Markets Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business September 29, 2021 Amicus Therapeutics Inc (NASDAQ: FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ: ARYD) and launch genetic... Via Benzinga The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug September 29, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... Via Benzinga Exposures Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
